RetinalGenix Technologies annual r&d spending
2020
2021
2022
2023
2024
2025
RetinalGenix Technologies R&D Spending Growth & History (RTGN)
RetinalGenix Technologies's r&d spending was $83,040 for fiscal 2025.
View full RetinalGenix Technologies company overviewRetinalGenix Technologies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $83,040 | −$290,231 | −77.75% |
| 2024 | 2024-12-31 | $373,271 | −$150,912 | −28.79% |
| 2023 | 2023-12-31 | $524,183 | −$285,072 | −35.23% |
| 2022 | 2022-12-31 | $809,255 | $61,447 | +8.22% |
| 2021 | 2021-12-31 | $747,808 | $316,251 | +73.28% |
| 2020 | 2020-12-31 | $431,557 | — | — |
RetinalGenix Technologies quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $66,406 | $51,976 | +360.19% |
| Q1 2026 | 2026-03-31 | $117,064 | $103,850 | +785.91% |
| Q4 2025 | 2025-12-31 | $34,942 | −$69,329 | −66.49% |
| Q3 2025 | 2025-09-30 | $20,454 | −$82,523 | −80.14% |
| Q2 2025 | 2025-06-30 | $14,430 | −$68,496 | −82.60% |
| Q1 2025 | 2025-03-31 | $13,214 | −$69,883 | −84.10% |
| Q4 2024 | 2024-12-31 | $104,271 | $50,375 | +93.47% |
| Q3 2024 | 2024-09-30 | $102,977 | $13,199 | +14.70% |
| Q2 2024 | 2024-06-30 | $82,926 | −$69,651 | −45.65% |
| Q1 2024 | 2024-03-31 | $83,097 | −$144,835 | −63.54% |
| Q4 2023 | 2023-12-31 | $53,896 | −$263,923 | −83.04% |
| Q3 2023 | 2023-09-30 | $89,778 | −$108,726 | −54.77% |
| Q2 2023 | 2023-06-30 | $152,577 | $17,138 | +12.65% |
| Q1 2023 | 2023-03-31 | $227,932 | $70,439 | +44.73% |
| Q4 2022 | 2022-12-31 | $317,819 | $135,575 | +74.39% |
| Q3 2022 | 2022-09-30 | $198,504 | −$2,395 | −1.19% |
| Q2 2022 | 2022-06-30 | $135,439 | −$24,502 | −15.32% |
| Q1 2022 | 2022-03-31 | $157,493 | −$47,231 | −23.07% |
| Q4 2021 | 2021-12-31 | $182,244 | — | — |
| Q3 2021 | 2021-09-30 | $200,899 | $102,003 | +103.14% |
| Q2 2021 | 2021-06-30 | $159,941 | — | — |
| Q1 2021 | 2021-03-31 | $204,724 | — | — |
| Q3 2020 | 2020-09-30 | $98,896 | — | — |
RetinalGenix Technologies r&d spending trends
Over the last five fiscal years, RetinalGenix Technologies's r&d spending decreased from $431,557 to $83,040, a change of −$348,517. The latest reported quarter, Q2 2026, shows $66,406.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RetinalGenix Technologies source filings ↗